Bill Long

Bill Long is a Senior Hematology Clinical Account Specialist at Pharmacyclics, an AbbVie Company, since July 2013, recognized for achieving the #1 national ranking in 2018 and #2 in 2023. In this role, Bill launched and promoted Imbruvica, an oral BTK inhibitor for various hematologic conditions, and Epkinly, a T-cell engaging bispecific antibody for adult patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Prior experience includes serving as an Oncology Diagnostic Sales Consultant at Genoptix from December 2009 to July 2013, an Executive Oncology Sales Consultant and Regional Sales Trainer at Bayer Healthcare from June 2006 to July 2009, and a Senior Oncology Sales Consultant and Regional Sales Trainer at Berlex Oncology from 1999 to 2006. Bill holds a BA in Social Sciences with minors in Biology and Music from Thomas Edison State University. Additional education includes studies at Kean University, Saint Peter's University, New Jersey City University, and Clemson University.